Role of molecular diagnostics in prostate cancer
Dr Elena Castro and Dr Shahneen Sandhu
2 Oct 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
30 Sep 2019
Bladder cancer: Latest advances in targeted therapies and precision medicine fro...
Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr...
30 Sep 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
30 Sep 2019
Role of biomarkers, targeted therapy and tumour mutations in the landscape of bl...
Prof Petros Grivas and Dr Michiel Van der Heijden
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
Implementing national cancer control plans
Dr Eduardo Cazap and Dr Lisa Stevens
24 Jun 2019
Comment: Enfortumab vedotin is an effective therapy and important development fo...
Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak
18 Jun 2019
